Say Hello!
Don’t be shy.

   

Charnwood Molecular Tag

Charnwood Molecular, a leading UK-based pre-clinical discovery CRO serving the global pharmaceutical and biotechnology market, has added a range of new solid-state capabilities to its portfolio through a new collaborative partnership with Barcelona-based Solitek. The sector-leading expertise and technology development within Solitek combines an excellent understanding...

Dr. Gary Allenby and Kathy Dodgson, founders and directors of Aurelia Bioscience, are pleased to announce that after 10 years of success as a standalone biology contract research organisation, the company has been acquired by its collaborator- Charnwood Molecular. To facilitate this agreement, Aurelia Bioscience,...

Charnwood Molecular, a leading UK-based pre-clinical discovery CRO servicing the global pharmaceutical and biotechnology market, is pleased to announce the acquisition of the assay development and biological screening provider, Aurelia Bioscience. The sector-leading expertise and technology development within Aurelia Bioscience will enable and enhance Charnwood’s provision...

Supporting the discovery and development of new therapeutics during the pandemic Nottingham-based contract research organisations (CROs) have strengthened their existing links to work together and support the discovery and development of new therapeutics during the pandemic. Many businesses have been impacted by the restrictions on the movement...